Taxanes Versus Androgen Receptor Therapy as Second-Line Treatment for Castrate-Resistant Metastatic Prostate Cancer After First-Line Androgen Receptor Therapy-Reference-Cited by-同舟云学术

Taxanes Versus Androgen Receptor Therapy as Second-Line Treatment for Castrate-Resistant Metastatic Prostate Cancer After First-Line Androgen Receptor Therapy

Published:2023-06 Issue:3 Volume:21 Page:349-356.e2
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Broyelle Antonin,Delanoy Nicolas,Bimbai André-Michel,Le Deley Marie-Cécile,Penel Nicolas,Villers Arnauld,Lebellec Loïc,Oudard Stéphane

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference27 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

3. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial;de Bono;Lancet,2010

4. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA;Oudard;J Clin Oncol,2017

5. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study;Fizazi;Lancet Oncol,2012

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Second-line treatment options in metastatic castration-resistant prostate cancer after progression on first-line androgen-receptor targeting therapies: A systematic review and Bayesian network analysis;Critical Reviews in Oncology/Hematology;2024-04

2. Evaluation of Second‐Line Treatment for Castration‐Resistant Prostate Cancer following the Administration of Upfront Androgen Receptor Signaling Inhibitors;Prostate Cancer;2024-01